ETON — Eton Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $424.25m
- $439.13m
- $39.01m
- 29
- 15
- 83
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 23.98 | ||
| PEG Ratio (f) | 0.25 | ||
| EPS Growth (f) | 1,868.34% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 17.37 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4.62% | ||
| Return on Equity | -19.16% | ||
| Operating Margin | -6.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.04 | 21.83 | 21.25 | 31.64 | 39.01 | 73.56 | 112.27 | 109.83% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +204.25 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Directors
- Norbert Riedel NEC (63)
- Sean Brynjelsen PRE (49)
- W. Troutman CFO (66)
- Jennifer Adams IND (52)
- Charles Casamento IND (75)
- Paul Maier IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 27th, 2017
- Public Since
- November 9th, 2018
- No. of Shareholders
- 4
- No. of Employees
- 31
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 26,817,535
- Address
- 21925 W Field Pkwy Ste 235, DEER PARK, 60010-7278
- Web
- https://etonpharma.com/
- Phone
- +1 8477877361
- Auditors
- KMJ Corbin & Company LLP
Upcoming Events for ETON
Eton Pharmaceuticals Inc Annual Shareholders Meeting
Eton Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Eton Pharmaceuticals Inc Earnings Release
Similar to ETON
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Eton Pharmaceuticals share price?
As of Today at 20:30 UTC, shares in Eton Pharmaceuticals are trading at $15.82. This share price information is delayed by 15 minutes.
How has the Eton Pharmaceuticals share price performed this year?
Shares in Eton Pharmaceuticals last closed at $15.82 and the price had moved by +407.05% over the past 365 days. In terms of relative price strength the Eton Pharmaceuticals share price has outperformed the S&P500 Index by +368.03% over the past year.
What are the analyst and broker recommendations for Eton Pharmaceuticals?
The overall consensus recommendation for Eton Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eton Pharmaceuticals dividend yield?
Eton Pharmaceuticals does not currently pay a dividend.
Does Eton Pharmaceuticals pay a dividend?
Eton Pharmaceuticals does not currently pay a dividend.
When does Eton Pharmaceuticals next pay dividends?
Eton Pharmaceuticals does not currently pay a dividend.
How do I buy Eton Pharmaceuticals shares?
To buy shares in Eton Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eton Pharmaceuticals?
As of the previous close price of $15.82, shares in Eton Pharmaceuticals had a market capitalisation of $424.25m.
Where are Eton Pharmaceuticals shares listed?
Here are the trading details for Eton Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ETON
What kind of share is Eton Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eton Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eton Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Eton Pharmaceuticals is $27.67. That is 74.91% above the last closing price of $15.82.
Analysts covering Eton Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $0.40 for the next financial year.
Find out moreWhat is the trend in the Eton Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eton Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +105.6%.
As of the last closing price of $15.82, shares in Eton Pharmaceuticals were trading +54.39% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eton Pharmaceuticals PE Ratio?
The Eton Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 23.98. The shares last closed at $15.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eton Pharmaceuticals?
Eton Pharmaceuticals' management team is headed by:
- Norbert Riedel - NEC
- Sean Brynjelsen - PRE
- W. Troutman - CFO
- Jennifer Adams - IND
- Charles Casamento - IND
- Paul Maier - IND